Gonçalves, J. C. N.Freitas, A. R. R.Fortuna, A. R.Menezes, M. B.Gramaça, J.Fernandes, I. C. GomesAngelo, I. C.Trabulo, C. F. P.Sousa, C. Xavier dePina, I. M. Matos2024-11-052024-11-052024-060923-7534http://hdl.handle.net/10400.1/26205Meeting Gastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology (ESMO) Background: Gemcitabine plus cisplatin (GC) was standard first-line treatment for advanced biliary tract cancers until recently, supported by the UK ABC-02 study. However, TOPAZ-1 showed survival improvement with Durvalumab plus GC. Nevertheless, a significant proportion of patients face challenges with GC tolerability, prompting into alternatives such as gemcitabine and carboplatin (GCb). Moreover, there remains a paucity of stratified data pertaining to cholangiocarcinomas (CCA). We analyzed 5-year trends to determine treatment rates and cisplatin use in the real world.engjournal article10.1016/j.annonc.2024.05.456